WO2021231827A3 - Sirna sequences targeting coronavirus-2 - Google Patents

Sirna sequences targeting coronavirus-2 Download PDF

Info

Publication number
WO2021231827A3
WO2021231827A3 PCT/US2021/032391 US2021032391W WO2021231827A3 WO 2021231827 A3 WO2021231827 A3 WO 2021231827A3 US 2021032391 W US2021032391 W US 2021032391W WO 2021231827 A3 WO2021231827 A3 WO 2021231827A3
Authority
WO
WIPO (PCT)
Prior art keywords
sirna sequences
sequences targeting
compositions
cov
sars
Prior art date
Application number
PCT/US2021/032391
Other languages
French (fr)
Other versions
WO2021231827A2 (en
Inventor
Jonathan WICKHAM
Louise BASKIN
Ioanna PAGANI
Pius Brzoska
Original Assignee
Life Technologies Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Technologies Corporation filed Critical Life Technologies Corporation
Publication of WO2021231827A2 publication Critical patent/WO2021231827A2/en
Publication of WO2021231827A3 publication Critical patent/WO2021231827A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Provided herein are compositions and methods useful for silencing RNA encoded by SARS-CoV-2. The compositions and methods can be used either in vitro (e.g., for research purposes), or in vitro (e.g., for therapeutic purposes). When administered to subjects who are afflicted with COVID-19, the compositions provided herein may facilitate recovery and/or ameliorate symptoms cause by SARS-CoV-2.
PCT/US2021/032391 2020-05-15 2021-05-14 Sirna sequences targeting coronavirus-2 WO2021231827A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063025220P 2020-05-15 2020-05-15
US63/025,220 2020-05-15

Publications (2)

Publication Number Publication Date
WO2021231827A2 WO2021231827A2 (en) 2021-11-18
WO2021231827A3 true WO2021231827A3 (en) 2022-02-17

Family

ID=76306019

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/032391 WO2021231827A2 (en) 2020-05-15 2021-05-14 Sirna sequences targeting coronavirus-2

Country Status (1)

Country Link
WO (1) WO2021231827A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220049251A1 (en) * 2020-05-20 2022-02-17 Nitto Denko Corporation dsRNA Directed to Coronavirus Proteins
US20230047473A1 (en) * 2021-07-14 2023-02-16 Toagosei Co., Ltd. siRNA based on RNA sequence of SARS-CoV-2 and use thereof
EP4151730A1 (en) * 2021-09-15 2023-03-22 Medesis Pharma Treatment of covid-19 with reverse micelle system comprising unmodified oligonucleotides
CN114703147A (en) * 2022-04-18 2022-07-05 扬州大学 anti-SARS-CoV-2 broad-spectrum neutralization monoclonal antibody and hybridoma cell strain, detection kit and application thereof
WO2023207615A1 (en) * 2022-04-26 2023-11-02 南京明德新药研发有限公司 Class of double-stranded rnai compounds containing overhang consisting of natural nucleotides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
AU2012242455A1 (en) 2011-04-15 2013-11-28 Molecular Transfer, Inc. Agents for improved delivery of nucleic acids to eukaryotic cells
EP3423438A4 (en) 2016-03-01 2020-05-06 Molecular Transfer, Inc. Plant virus movement proteins and methods of using the same
US10036024B2 (en) 2016-06-03 2018-07-31 Purdue Research Foundation siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHOWDHURY UMAR FARUQ ET AL: "A Computational Approach to Design Potential siRNA Molecules as a Prospective Tool for Silencing Nucleocapsid Phosphoprotein and Surface Glycoprotein Gene of SARS-CoV-2", BIORXIV 2020.04.10.036335, 21 April 2020 (2020-04-21), pages 1 - 12, XP055825705, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.04.10.036335v2.full.pdf> [retrieved on 20210719], DOI: 10.1101/2020.04.10.036335 *
CYNTHIA LIU ET AL: "Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases", ACS CENTRAL SCIENCE, vol. 6, no. 3, 12 March 2020 (2020-03-12), pages 315 - 331, XP055724944, ISSN: 2374-7943, DOI: 10.1021/acscentsci.0c00272 *
FARUQ CHOWDHURY UMAR ET AL: "Supplementary Table 5: A Computational Approach to Design Potential siRNA Molecules as a Prospective Tool for Silencing Nucleocapsid Phosphoprotein and Surface Glycoprotein Gene of SARS-CoV-2", 21 April 2020 (2020-04-21), pages 1 - 4, XP055825903, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.04.10.036335v2.supplementary-material?versioned=true> [retrieved on 20210720] *
FARUQ CHOWDHURY UMAR ET AL: "Supplementary Table 7: A Computational Approach to Design Potential siRNA Molecules as a Prospective Tool for Silencing Nucleocapsid Phosphoprotein and Surface Glycoprotein Gene of SARS-CoV-2", 21 April 2020 (2020-04-21), pages 1 - 4, XP055825908, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.04.10.036335v2.supplementary-material?versioned=true> [retrieved on 20210720] *
HODGSON JOHN: "The pandemic pipeline", NATURE BIOTECHNOLOGY, GALE GROUP INC, NEW YORK, vol. 38, no. 5, 20 March 2020 (2020-03-20), pages 523 - 532, XP037154993, ISSN: 1087-0156, [retrieved on 20200320], DOI: 10.1038/D41587-020-00005-Z *
JIANG YUANYUAN ET AL: "Repurposing therapeutics to identify novel inhibitors targeting 2'-O-ribose methyltransferase nsp16 of SARS-CoV-2", 1 May 2020 (2020-05-01), XP055852254, Retrieved from the Internet <URL:https://pdfs.semanticscholar.org/12a2/99c451b073596c37e9c1531d11fe14f5f9b5.pdf?_ga=2.154067056.912084237.1634547312-779291575.1634547312> [retrieved on 20211018] *
LIU CYNTHIA ET AL: "Table S1. Distribution of RNAi patents related to SARS and MERS in the CAS content collection Patent Number RNAi type Target CAS Patent Title Organization", RESEARCH AND DEVELOPMENT ON THERAPEUTIC AGENTS AND VACCINES FOR COVID-19 AND RELATED HUMAN CORONAVIRUS DISEASES, 12 March 2002 (2002-03-12), XP055817418, Retrieved from the Internet <URL:https://pubs.acs.org/doi/10.1021/acscentsci.0c00272> [retrieved on 20210623] *
V. D. MENACHERY ET AL: "Attenuation and Restoration of Severe Acute Respiratory Syndrome Coronavirus Mutant Lacking 2'-O-Methyltransferase Activity", JOURNAL OF VIROLOGY, vol. 88, no. 8, 29 January 2014 (2014-01-29), pages 4251 - 4264, XP055215583, ISSN: 0022-538X, DOI: 10.1128/JVI.03571-13 *

Also Published As

Publication number Publication date
WO2021231827A2 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
WO2021231827A3 (en) Sirna sequences targeting coronavirus-2
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
MX2019002904A (en) High purity rna compositions and methods for preparation thereof.
UY31543A1 (en) SYSTEM OF ADMINISTRATION OF RNAI OF INTERFERENCE AND USES OF THE SAME
MX348817B (en) Methods for treating cancer and non-neoplastic conditions.
WO2015149944A3 (en) Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
ZA201908445B (en) Recombinant adenoviruses carrying transgenes
UA89957C2 (en) Chimeric adenoviruses for use in cancer treatment
MX343802B (en) Non-natural amino acid replication-dependent microorganisms and vaccines.
UA104634C2 (en) Pegylated l-asparaginase
WO2009129470A3 (en) Methods for treating herpes virus infections
JO2755B1 (en) Use of 2-6 (3- amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrilfor treating diabetes,cancer , autoimmune disorders and hiv infection
MX2011007702A (en) Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration.
MX339205B (en) Stabilized liquid and lyophilized adamts13 formulations.
EP2700708A3 (en) Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
TW200738253A (en) Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
MX337041B (en) Strains and methods for improving ruminant health and/or performance.
PH12014502569A1 (en) Method for treating non-small cell lung cancer
EP4289475A3 (en) Methods of treating fabry disease in patients having a mutation in the gla gene
PH12015502500A1 (en) Bacteriophage therapy
BR112014029954A2 (en) treatment of solid tumors using coenzyme q10
WO2010000127A9 (en) Method to induce and expand therapeutic alloantigen- specific human regulatory t cells in large-scale
MX2008008768A (en) Treatment of hiv.
GB0418388D0 (en) Cell therapy
WO2019098759A3 (en) Transformed human cell and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21730738

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21730738

Country of ref document: EP

Kind code of ref document: A2